OncoMatch/Clinical Trials/NCT06526338
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
Is NCT06526338 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies 1.0% IP-001 for for hepatocellular carcinoma.
Treatment: 1.0% IP-001 for — The purpose of this study is to evaluate the safety and efficacy of administration of intratumoral IP-001 injection at different dosages (volume and concentration) following local microwave ablation (MWA) or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
absolute neutrophil count ≥1500/µl or anc of ≤1500/µl if there is a stable medical history of neutropenia per provider discretion; platelets ≥40,000/µl; hemoglobin ≥8.0 g/dl
Kidney function
creatinine or measured or calculated creatinine clearance (gfr can also be used in place of creatinine or crcl) ≤1.5 × uln or gfr ≥30 ml/min for patients with creatinine levels >1.5 × institutional uln
Liver function
total bilirubin ≤2 mg/dl or direct bilirubin ≤uln for patients with total bilirubin levels >2 mg/dl; ast (sgot) and alt (sgpt) ≤5 × uln; albumin >2.6 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Louisville · Louisville, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06526338 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages